Search results
Results from the WOW.Com Content Network
PSA Screening. Clinicians should engage in shared decision-making (SDM) with people for whom prostate cancer screening would be appropriate and proceed based on a person’s values and preferences. (Clinical Principle) When screening for prostate cancer, clinicians should use PSA as the first screening test.
The discussion about screening should take place at: Age 50 for men who are at average risk of prostate cancer and are expected to live at least 10 more years Age 45 for men at high risk of developing prostate cancer.
This guideline provides recommendations for prostate cancer screening in different groups based on their age range and risk criteria, with an emphasis on SDM.
LAST UPDATED: Dec 21, 2023. The Task Force keeps recommendations as current as possible by routinely updating existing recommendations and developing new recommendations. A multistep process is followed for each recommendation.
This guideline includes: Focus on early detection with an emphasis on PSA-based screening. Considerations for initial and repeat biopsy, with the goal of identifying clinically significant prostate cancer. Discussion of biopsy technique. Reference figures outlining the recommended screening process and decision points.
Prostate-specific antigen (PSA)-based prostate cancer screening in combination with shared decision-making (SDM) is recommended. Current data regarding risk from population-based cohorts provide a basis for longer screening intervals and tailored screening, and the use of available online risk calculators is encouraged.
Prostate-specific antigen (PSA) screening should involve shared decision making with consideration of the risks and benefits of screening and patient preferences.